Conference abstractPublished 2018
Molecular targeting and personalized cancer therapeutics
Kent State University, United States. Ph.D., RPh, FRSC
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Targeted cancer therapeutics are designed to interfere with molecular targets with a goal of fighting tumor cells with more precision and fewer side effects. Cancer biomarkers are most relevant for identifying patients who are likely to benefit from a given treatment (right drug for the right patient). Recently approved cancer therapies, that act on specific molecular targets, along with FDA-approved companion diagnostics, are presented. These molecular pathways are broadly classified as either 1) monoclonal antibodies that target transmembrane receptors or extracellular growth factors or 2) small molecules that penetrate cell membrane and block and interfere with the enzymatic activity of the target proteins. Inhibitors of PI3K (phosphatidylinositol 3-kinase), CDK (cyclin-dependent kinase), PARP (DNA repair; poly ADP ribose polymerase), and IDH2 (isocitrate dehydrogenase-2) are presented. Also, large molecule immuno-oncology receptor binding is also discussed.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutical Sciences & Emerging Drugs
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Salah M. Blaih”
